Advancing understanding and treatment of sickle cell disease through multiple research approaches
Our genomics research focuses on identifying and utilizing genetic differences between patients to discover new drug targets that can increase fetal hemoglobin levels. This work has progressed from initial genetic associations to successful clinical trials, including the development of a treatment that's safe during pregnancy.
We investigate the complex mechanisms behind chronic pain development in sickle cell disease. Our research examines how years of episodic pain crises can lead to permanent changes in pain signaling, particularly focusing on the role of microglial cells.
Our lab develops innovative biomarkers to evaluate red cell function and therapy effectiveness. Using advanced technologies like oxygen gradient ektacytometry, we measure red cell flexibility and oxygen tolerance to assess treatment outcomes.
We're at the forefront of evaluating and improving gene therapy approaches for sickle cell disease. Our work includes investigating safety concerns, developing optimization strategies, and establishing new standards for cure definition.
